Hypoxic pulmonary hypertension (HPH) is a refractory disease. The main symptoms of HPH are pulmonary vascular remodeling and persistent increase in pulmonary vascular resistance, which can lead to progressive right ventricular hypertrophy and even death. The role of platelet-derived growth factor-BB/ERK/hypoxia-inducible factor-1α signaling pathway in the occurrence and development of hypoxic pulmonary hypertension has become the focus of attention. The hyperbaric treatment provides new ideas. This review mainly studies the research progress of the PDGF-BB/ERK/HIF-1α signaling pathway in pulmonary hypertension in recent years and conducts related research.

Guo Xin, Li Mingxia. Research progress of PDGF-BB/ERK/HIF-1α signaling pathway in hypoxic pulmonary hypertension. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 2: 19-23. https://doi.org/10.25236/IJFM.2023.050204.

[1] Martinho S, Adão R, Leite M A F, et al. Persistent Pulmonary Hypertension of the Newborn: Pathophysiological Mechanisms and Novel Therapeutic Approaches. Frontiers in pediatrics, 2020,8.

[2] Wang L, Zheng Q, Yuan Y, et al. Effects of 17beta-estradiol and 2-methoxyestradiol on the oxidative stress-hypoxia inducible factor-1 pathway in hypoxic pulmonary hypertensive rats Exp Ther Med, 2017, 13(5):2537-2543.

[3] Pullamsetti S S, Savai R, Seeger W, et al. Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs Am J Respir Crit Care Med, 2017,195(4):425-437.

[4] Stenmark K R, Frid M G, Graham B B, et al. Dynamic and diverse changes in the functional properties of vascular smooth muscle cells in pulmonary hypertension Cardiovasc Res, 2018,114(4):551-564.

[5] Veith C, Schermuly R T, Brandes R P, et al. Molecular mechanisms of hypoxia-inducible factor-induced pulmonary arterial smooth muscle cell alterations in pulmonary hypertension J Physiol, 2016, 594(5):1167-1177.

[6] Pedersen J, Hedegaard E R, Simonsen U, et al. Current and Future Treatments for Persistent Pulmonary Hypertension in the Newborn. Basic & clinical pharmacology & toxicology, 2018,123(4).

[7] Shimoda L A. Cellular Pathways Promoting Pulmonary Vascular Remodeling by Hypoxia Physiology (Bethesda), 2020,35(4):222-233.

[8] Berg J T,  Breen E C ,  Fu Z , et al. Alveolar Hypoxia Increases Gene Expression of Extracellular Matrix Proteins and Platelet-derived Growth Factor-B in Lung Parenchyma American Thoracic Society, 1998(6).

[9] Kunichika N, Landsberg J W, Yu Y, et al. Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytes. American journal of respiratory and critical care medicine, 2004,170(10).

[10] Wang C, Liu Y, He D. Diverse effects of platelet-derived growth factor-BB on cell signaling pathways Cytokine, 2019,113:13-20.

[11] Hu W, Huang Y. Targeting the platelet-derived growth factor signalling in cardiovascular disease Clin Exp Pharmacol Physiol, 2015,42(12):1221-1224.

[12] Zhao F, Xu S, Zhang C, et al. PDGF mediates pulmonary arterial smooth muscle cell proliferation and migration by regulating NFATc2. Molecular medicine reports, 2020,23(1).

[13] Alberts, Bruce, Wilson, et al. 6BBA0381: Biology of Cancer (Year 2014/15).

[14] Veith C, Schermuly RT, Brandes RP, et al. Molecular mechanisms of hypoxia-inducible factor-induced pulmonary arterial smooth muscle cell alterations in pulmonary hypertensionJ Physiol, 2016, 594(5): 1167-77.

[15] Cui C, Zhang H, Guo L N, et al. Inhibitory effect of NBL1 on PDGF-BB-induced human PASMC proliferation through blockade of PDGFbeta-p38MAPK pathway Biosci Rep, 2016,36(4).

[16] Perros F, Montani D, Dorfmuller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension Am J Respir Crit Care Med, 2008,178(1):81-88.

[17] Antoniu S A. Targeting PDGF pathway in pulmonary arterial hypertension. Expert opinion on therapeutic targets, 2012,16(11).

[18] Xing A, Hu X, Shi Y, et al. Implication of PDGF signaling in cigarette smoke-induced pulmonary arterial hypertension in rat. Inhalation toxicology, 2012,24(8).

[19] Barst R J. PDGF signaling in pulmonary arterial hypertension Journal of Clinical Investigation, 2005,115(10).

[20] Montani D ,  Perros F , P. Dorfmüller, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension Elsevier Masson, 2008(9).

[21] Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. The Journal of clinical investigation, 2012, 122(12).

[22] Deng L, Chen J, Wang T, et al. PDGF/MEK/ERK axis represses Ca(2+) clearance via decreasing the abundance of plasma membrane Ca(2+) pump PMCA4 in pulmonary arterial smooth muscle cells Am J Physiol Cell Physiol, 2021,320(1):C66-C79.

[23] Taylor S S, Kornev A P. Protein kinases: evolution of dynamic regulatory proteins Trends Biochem Sci, 2011,36(2):65-77.

[24] Busca R, Christen R, Lovern M, et al. ERK1 and ERK2 present functional redundancy in tetrapods despite higher evolution rate of ERK1 BMC Evol Biol, 2015,15:179.

[25] Tanya H, Rahul B, Sujatha V, et al. Xanthine oxidase-derived ROS upregulate Egr-1 via ERK1/2 in PA smooth muscle cells; model to test impact of extracellular ROS in chronic hypoxia. PLoS ONE, 2017,6(11).

[26] Chenghui Z, Yu C, Wenying K, et al. Mir-455-3p-1 represses FGF7 expression to inhibit pulmonary arterial hypertension through inhibiting the RAS/ERK signaling pathway Journal of Molecular and Cellular Cardiology, 2019,130.

[27] Xing J, Wang M, Hong J, et al. TRPM7 channel inhibition exacerbates pulmonary arterial hypertension through MEK/ERK pathway Aging (Albany NY), 2019,11(12):4050-4065.

[28] Chen J, Song M, Qian D, et al. Atorvastatin rescues pulmonary artery hypertension via inhibiting the AKT/ERK-dependent PDGF-BB/HIF-1alpha axis Panminerva Med, 2021.

[29] Zhao Y, Xiang R, Peng X, et al. Transection of the cervical sympathetic trunk inhibits the progression of pulmonary arterial hypertension via ERK-1/2 Signalling Respir Res, 2019,20(1):121.

[30] Feng W, Wang J, Yan X, et al. ERK/Drp1-dependent mitochondrial fission contributes to HMGB1-induced autophagy in pulmonary arterial hypertension Cell Prolif, 2021, 54(6): e13048.

[31] Cheng C C, Chi P L, Shen M C, et al. Caffeic Acid Phenethyl Ester Rescues Pulmonary Arterial Hypertension through the Inhibition of AKT/ERK-Dependent PDGF/HIF-1alpha In Vitro and In Vivo Int J Mol Sci, 2019, 20(6).

[32] Semenza, Gregg, L. Involvement of Hypoxia- Inducible Factor 1 in Pulmonary Pathophysiology. Chest, 2005.

[33] Prabhakar N R, Semenza G L. Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2 Physiol Rev, 2012, 92(3): 967-1003.

[34] Brusselmans K, Compernolle V, Tjwa M, et al. heterozygous deficiency of hypoxia-inducible factor-2α protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia 2017.

[35] Yu A, Shimoda L, Iyer N, et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. The Journal of clinical investigation, 1999, 103(5):691-6.

[36] Awad KS, West JD, De JPV, et al. Novel signaling pathways in pulmonary arterial hypertension (2015 Grover Conference Series) Pulm Circ, 2016, 6(3): 285-94.

[37] Wang L, Zhou Y, Li M, et al. Expression of hypoxia-inducible factor-1alpha, endothelin-1 and adrenomedullin in newborn rats with hypoxia-induced pulmonary hypertension Exp Ther Med, 2014, 8(1): 335-339.

[38] Wang L, Li M. Roles of heat shock protein 70 toward hypoxia-inducible factor 1α (HIF-1α) blockade in newborn rats with hypoxia-induced pulmonary hypertension INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11(12): 13520-13527.

[39] Ball M K, Waypa G B, Mungai P T, et al. Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1α. Am J Respir Crit Care Med, 2014, 189(3): 314-324.

[40] Jernigan N L, Resta T C, Gonzalez B L. Altered Redox Balance in the Development of Chronic Hypoxia-induced Pulmonary Hypertension Adv Exp Med Biol, 2017, 967: 83-103.

[41] Shimoda, Larissa A, Manalo, et al. Partial HIF-1alpha deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia. American Journal of Physiology: Lung Cellular & Molecular Physiology, 2001.

[42] Wang, J. Hypoxia Inducible Factor 1 Mediates Hypoxia-Induced TRPC Expression and Elevated Intracellular Ca2+ in Pulmonary Arterial Smooth Muscle Cells Circulation Research, 2006, 98(12): 1528-37.

[43] Chen X, Yao J M, Fang X, et al. Hypoxia promotes pulmonary vascular remodeling via HIF-1alpha to regulate mitochondrial dynamics J Geriatr Cardiol, 2019,16(12): 855-871.

[44] Luo Y, Teng X, Zhang L, et al. CD146-HIF-1alpha hypoxic reprogramming drives vascular remodeling and pulmonary arterial hypertension Nat Commun, 2019, 10(1): 3551.

[45] Cheng C C, Chi P L, Shen M C, et al. Caffeic Acid Phenethyl Ester Rescues Pulmonary Arterial Hypertension through the Inhibition of AKT/ERK-Dependent PDGF/HIF-1alpha In Vitro and In Vivo Int J Mol Sci, 2019, 20(6).